Health

Add as a preferred source on Google

FDA Lists Class I Recall for Luna G3 BPAP System Devices

React Health says 7,533 devices were distributed in the United States and Puerto Rico. The reporting fault occurs when Targeted VT is enabled.

Updated 2 min read
A Luna G3 BPAP device and its SD card sit in a respiratory therapy clinic in the United States. / TokenPost.ai
A Luna G3 BPAP device and its SD card sit in a respiratory therapy clinic in the United States. / TokenPost.ai

A pressure-reporting fault in certain Luna G3 bilevel positive airway pressure (BPAP) devices could leave U.S. clinicians with inaccurate therapy records, prompting a Class I recall listed by the Food and Drug Administration (FDA).

React Health says 7,533 units of model LG3800-30VT were distributed in the United States and Puerto Rico. When Targeted VT is enabled, the devices may fail to save actual delivered pressure to an internal SD card or send it to React Health Connect. The company says the reporting error occurs when the feature is active.

The FDA database identifies 3B Medical, Inc. as the recalling firm and lists Nov. 12, 2026, as the posting date. React Health published a correction update Nov. 17, following an initial communication on Oct. 8.

React Health says inaccurate historical pressure reports could lead a clinician to adjust therapy settings based on incorrect information, potentially delaying therapy until the settings are corrected. The company reported 15 complaints and two serious adverse reports associated with the issue; its notice does not say the fault caused those reports.

Firmware G3-2.00.80 is intended to correct the reporting problem and can be installed with an update SD card, according to React Health. The update does not change data collected before installation, and the company’s instructions call for providers to erase historical usage data afterward.

React Health directs patients to seek guidance from their health care or equipment provider and follow their prescribed therapy until then. It says patients should not change settings or stop respiratory therapy without clinical guidance. Providers are instructed to discontinue Targeted VT on affected devices and coordinate patient support.

Related articles

View all